Get the Stockscreener App
0.00
100.00%
-7.02
After Hours:
7.02
7.02
+
Accolade Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
See More
Previous Close:
$7.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$562.77M
Revenue:
$414.29M
Net Income/Loss:
$-99.81M
P/E Ratio:
0.00
EPS:
-1.3348
Net Cash Flow:
$-28.65M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$8.24
Accolade Inc Stock (ACCD) Company Profile
Name
Accolade Inc
Sector
Industry
Phone
610-834-2989
Address
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Compare ACCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACCD
Accolade Inc
|
0.00 | 562.77M | 414.29M | -99.81M | -28.65M | -1.3348 |
|
VEEV
Veeva Systems Inc
|
231.64 | 35.11B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
57.75 | 9.83B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
54.29 | 7.48B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
86.42 | 7.22B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.03 | 6.10B | 906.14M | -52.62M | 89.62M | -0.3621 |
Accolade Inc Stock (ACCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Reiterated | Needham | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-17-24 | Resumed | DA Davidson | Neutral |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| May-24-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Mar-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-09-23 | Downgrade | Jefferies | Buy → Hold |
| Feb-02-23 | Initiated | Raymond James | Outperform |
| Sep-08-22 | Resumed | Piper Sandler | Overweight |
| Sep-07-22 | Initiated | Truist | Buy |
| Aug-12-22 | Initiated | DA Davidson | Buy |
| May-02-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-29-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-29-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-29-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-11-22 | Initiated | Wells Fargo | Underweight |
| Apr-07-22 | Initiated | Guggenheim | Neutral |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-11-22 | Initiated | Goldman | Buy |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Sep-30-21 | Initiated | Berenberg | Buy |
| Sep-17-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-15-21 | Initiated | Needham | Buy |
| Mar-11-21 | Resumed | Goldman | Buy |
| Jan-15-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Initiated | Canaccord Genuity | Buy |
| Sep-22-20 | Initiated | DA Davidson | Buy |
| Jul-27-20 | Initiated | BofA Securities | Buy |
| Jul-27-20 | Initiated | Credit Suisse | Neutral |
| Jul-27-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | Morgan Stanley | Overweight |
| Jul-27-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Initiated | Robert W. Baird | Outperform |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
View All
Accolade Inc Stock (ACCD) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Adventus Singapore Pte. Ltd. bags accolade at SBR National Business Awards 2025 - Singapore Business Review
Accolade president Robert Cavanaugh sells shares worth $3,857 - MSN
Digital health startup Transcarent takes Accolade private in $621 million deal - MSN
MedEthix Inc earns two accolades at Healthcare Asia Pharma Awards 2025 - Healthcare Asia Magazine
Transcarent finalizes merger with Accolade - MobiHealthNews
Telehealth startup completes $621 million acquisition of Seattle's Accolade - The Business Journals
Accolade completes merger with Transcarent, shifts control By Investing.com - Investing.com Canada
Accolade completes merger with Transcarent, shifts control - Investing.com
Transcarent Completes Merger With Accolade - Business Wire
AcCOLADE president Robert Cavanaugh sells $3,845 in stock By Investing.com - Investing.com Canada
Accolade EVP general counsel sells $2,642 in stock - Investing.com Australia
Accolade EVP general counsel sells $2,642 in stock By Investing.com - Investing.com South Africa
AcCOLADE president Robert Cavanaugh sells $3,845 in stock - Investing.com
Accolade’s CFO Stephen Barnes sells shares worth $3,013 By Investing.com - Investing.com South Africa
Accolade’s CFO Stephen Barnes sells shares worth $3,013 - Investing.com
Accolade, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Accolade (ACCD) - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Accolade, Inc. (ACCD) - ACCESS Newswire
Is Accolade Inc. (NASDAQ:ACCD) the Best Performing Stock So Far In 2025? - MSN
Accolade shareholders approve merger with Transcarent By Investing.com - Investing.com India
Accolade Stockholders Approve Merger with Transcarent - TipRanks
Accolade Shareholders Greenlight Merger With Transcarent - MarketScreener
Accolade shareholders approve merger with Transcarent - Investing.com
Accolade Stockholders Approve Merger Between Accolade and Transcarent - GlobeNewswire
GLAZER CAPITAL, LLC Acquires Significant Stake in Accolade Inc - GuruFocus
Accolade president Robert Cavanaugh sells $1,264 in stock By Investing.com - Investing.com Australia
Accolade CFO Stephen H. Barnes sells $991 worth of stock By Investing.com - Investing.com Australia
Accolade CEO Rajeev Singh sells $2,018 in stock By Investing.com - Investing.com Australia
Accolade president Robert Cavanaugh sells $1,264 in stock - Investing.com India
Accolade CEO Rajeev Singh sells $2,018 in stock - Investing.com India
Accolade CFO Stephen H. Barnes sells $991 worth of stock - Investing.com
STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of ACCD, SKGR, AVAV, WMPN to Act Now - The Malaysian Reserve
Do Options Traders Know Something About Accolade (ACCD) Stock We Don't? - Barchart
AcCOLADE CFO Stephen Barnes sells $1,769 in stock By Investing.com - Investing.com Canada
Accolade Inc Stock: $621M Transcarent Buyout Sends Shares Soaring - sharewise
Accolade president Robert Cavanaugh sells shares worth $1,734 By Investing.com - Investing.com Canada
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of ACCD, SKGR, AVAV, WMPN to Act Now - GlobeNewswire Inc.
Accolade Inc Stock (ACCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):